{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:46:01Z","timestamp":1792007161985,"version":"4.4.0"},"reference-count":39,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer is the second leading cause of male deaths in the Western world and the most commonly detected cancer in males. Recent studies have pointed out that DNA methylation and TMPRSS2-ERG fusion transcript, have a high presence among prostate tumor cells. It is estimated that these two molecular mechanisms could be used as potential markers for early detection of malignancy, and\/or progression of prostate cancer disease.<\/jats:p>\n                  <jats:p>\n                    The study aimed to test the presence of the DNA methylation and TMPRSS2-ERG fusion transcript in patients with prostate cancer, as a baseline database for further genetic examination. This prospective clinical study focused on a random sample of 88 patients with prostate carcinoma. For the detection of methylation status in 26 tumor suppressor genes (\n                    <jats:italic>TP73, CASP8, VHL, RARB, MLH1, RASSF1, FHIT, APC, SLC9A2-2, ESR1, CDKN2A, CDKN2B, DAPK1, KLLN, PTEN, CD44, GSTP1, ATM, CADM1, CDKN1B, CHFR, BRCA2, CDH13, HIC1, BRCA1 and TIMP3<\/jats:italic>\n                    ), in CaP patients the Multiplex Ligation-Dependent Probe Amplification (MLPA) analyses was performed. All samples were conducted on a Real-time PCR analysis for the detection of the TMPRSS2-ERG fusion transcript. Additionally, the data from the histopathology results of tissues, and level of prostate-specific antigen (PSA) in blood were used.\n                  <\/jats:p>\n                  <jats:p>\n                    Genome-wide DNA methylation profiles were detected in 10 out of 26 genes:\n                    <jats:italic>GSTP1<\/jats:italic>\n                    was\n                    <jats:italic\/>\n                    found in 53,4 % of samples,\n                    <jats:italic>RARB<\/jats:italic>\n                    in 44,32%,\n                    <jats:italic>RASSF1<\/jats:italic>\n                    in 63,6%,\n                    <jats:italic>APC<\/jats:italic>\n                    in 42%,\n                    <jats:italic>CDH13<\/jats:italic>\n                    in 39,7%,\n                    <jats:italic>CASP8<\/jats:italic>\n                    in\n                    <jats:italic>25<\/jats:italic>\n                    %,\n                    <jats:italic>CD44<\/jats:italic>\n                    -12,5%,\n                    <jats:italic>TIMP3<\/jats:italic>\n                    -2%,\n                    <jats:italic>ESR1<\/jats:italic>\n                    -9% and\n                    <jats:italic>CADM1<\/jats:italic>\n                    -1%. Cohen\u2019s (\u03ba) fair agreement test has shown a linear positive moderate correlation between PSA level and 4 genes (\n                    <jats:italic>RARB, APC, GSTP1<\/jats:italic>\n                    , and\n                    <jats:italic>CDH13<\/jats:italic>\n                    ), and a significant linear positive moderate correlation between Gleason Score and 9 methylated genes (GSTP\n                    <jats:italic>1<\/jats:italic>\n                    ,\n                    <jats:italic>RARB<\/jats:italic>\n                    ,\n                    <jats:italic>RASSF1<\/jats:italic>\n                    ,\n                    <jats:italic>APC, CDH13<\/jats:italic>\n                    ,\n                    <jats:italic>CASP8, IMP3<\/jats:italic>\n                    ,\n                    <jats:italic>ESR1<\/jats:italic>\n                    , and\n                    <jats:italic>CADM1),<\/jats:italic>\n                    except for gene CD44. TMPRSS2-ERG fused transcript was detected in 32 out of 88 (36,4%) of the samples. There were no significant differences between patients with\/without detected TMPRSS2-ERG fusion related to Gleason score and PSA level. In conclusion, additional studies need to be performed in appropriately powered clinical cohorts that will define the positive diagnostic meaning of TMPRSS2-ERG fusion transcript, point to the sites in the genome that are under the influence of DNA methylation, in that manner offering additional information for further management of the CaP disease.\n                  <\/jats:p>","DOI":"10.2478\/bjmg-2026-0014","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:57:33Z","timestamp":1792004253000},"page":"63-70","source":"Crossref","is-referenced-by-count":0,"title":["DNA Methylation and TMPRSS2-ERG Fusion Status in Patients with Prostate Cancer from The Republic of North Macedonia"],"prefix":"10.2478","volume":"29","author":[{"given":"A","family":"Trifunovski","sequence":"first","affiliation":[{"name":"University Clinic of Urology , Medical Faculty, University of \u201cSs. Cyril and Methodius\u201d \u2013 Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gavrilovska-Brzanov","sequence":"additional","affiliation":[{"name":"University Clinic for Traumatology , Orthopedic Diseases, Anesthesia, Reanimation, Intensive Care and Emergency Centre, Medical Faculty, University of \u201cSs. Cyril and Methodius\u201d \u2013 Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Dohchev","sequence":"additional","affiliation":[{"name":"University Clinic of Urology , Medical Faculty, University of \u201cSs. Cyril and Methodius\u201d \u2013 Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Janculev","sequence":"additional","affiliation":[{"name":"University Clinic of Urology , Medical Faculty, University of \u201cSs. Cyril and Methodius\u201d \u2013 Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Trajkovski","sequence":"additional","affiliation":[{"name":"University Clinic of Urology , Medical Faculty, University of \u201cSs. Cyril and Methodius\u201d \u2013 Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Vujicic","sequence":"additional","affiliation":[{"name":"University Clinic of Urology , Medical Faculty, University of \u201cSs. Cyril and Methodius\u201d \u2013 Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Severova Andreevska","sequence":"additional","affiliation":[{"name":"University Clinic of Nephrology , Medical Faculty, University of \u201cSs. Cyril and Methodius\u201d \u2013 Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ambardjieva","sequence":"additional","affiliation":[{"name":"University Clinic for Surgical Diseases \u201cSt. Naum Ohridski, Medical Faculty, University of \u201cSs. Cyril and Methodius\u201d \u2013 Skopje , R. N. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Dodikj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cardiology Unit, General Hospital - Kumanovo , North Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"2026101418572579994_j_bjmg-2026-0014_ref_001","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71\u2013 96","DOI":"10.3322\/CA.2007.0010"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_002","doi-asserted-by":"crossref","unstructured":"Lumey LH, Pittman B, Wynder EL. Alcohol use and prostate cancer in U.S. whites: no association in a confirmatory study. Prostate 1998;36(4):250\u2013255.","DOI":"10.1002\/(SICI)1097-0045(19980901)36:4<250::AID-PROS6>3.0.CO;2-J"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_003","doi-asserted-by":"crossref","unstructured":"de Lamirande, E., O\u2019Flaherty, C. Sperm activation: role of reactive oxygen species and kinases. Biochim Biophys Acta. 2008;1784:106\u2013115.","DOI":"10.1016\/j.bbapap.2007.08.024"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_004","doi-asserted-by":"crossref","unstructured":"Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297\u2013 301","DOI":"10.1097\/01.ju.0000139993.51181.5d"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_005","doi-asserted-by":"crossref","unstructured":"Roupret M, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 2008; 122: 952\u2013 6","DOI":"10.1002\/ijc.23196"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_006","doi-asserted-by":"crossref","unstructured":"Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, et al. Effect of DNA methylation on identification of aggressive prostate cancer. Urology 2008; 72: 1234\u2013 9","DOI":"10.1016\/j.urology.2007.12.060"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_007","doi-asserted-by":"crossref","unstructured":"Nygren AO, Ameziane N, Duarte HM, et al. Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP, Errami A Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005 33(14):e128","DOI":"10.1093\/nar\/gni127"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_008","doi-asserted-by":"crossref","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. et al. Global cancer statistics. CA Cancer J Clin 2011;61:69\u201390.","DOI":"10.3322\/caac.20107"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_009","doi-asserted-by":"crossref","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277\u2013300.","DOI":"10.3322\/caac.20073"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_010","doi-asserted-by":"crossref","unstructured":"Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624\u20139.","DOI":"10.1038\/nature01075"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_011","doi-asserted-by":"crossref","unstructured":"Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644\u20138.","DOI":"10.1126\/science.1117679"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_012","doi-asserted-by":"crossref","unstructured":"Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S,.et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66: 8337\u201341.","DOI":"10.1158\/0008-5472.CAN-06-1482"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_013","doi-asserted-by":"crossref","unstructured":"Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2\/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer. 2006;45:717\u2013719.","DOI":"10.1002\/gcc.20329"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_014","doi-asserted-by":"crossref","unstructured":"M. Folini, P. Gandellini, N. Longoni, Profumo V, Callari M, Pennati M, et al. miR-21: an oncomir on strike in prostate cancer. Mol Cancer. 2010, 9:12.","DOI":"10.1186\/1476-4598-9-12"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_015","doi-asserted-by":"crossref","unstructured":"Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS Gene Aberrations in Androgen-Independent Metastatic Prostate Cancer. Cancer Res. 2008;68:3584\u20133590","DOI":"10.1158\/0008-5472.CAN-07-6154"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_016","doi-asserted-by":"crossref","unstructured":"Liu B, Gu X, Huang T, Luan Y, Ding X. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1. Oncology Reports Jan 2017; 37(1): 201\u2013208.","DOI":"10.3892\/or.2016.5277"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_017","doi-asserted-by":"crossref","unstructured":"Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, et al.Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer. Anticancer Research. Sep 2016;36(9): 4787\u20134793.","DOI":"10.21873\/anticanres.11037"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_018","doi-asserted-by":"crossref","unstructured":"Saram\u00e4ki O.R, Harjula A.E, Martikainen P.M, Vessella R.L, Tammela T.L.J. Tapio Visakorpi. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis. Clin Cancer Res. Jun 2008;14(11): 3395\u20133400.","DOI":"10.1158\/1078-0432.CCR-07-2051"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_019","doi-asserted-by":"crossref","unstructured":"Krstanoski1 Z, Vokac N.K. , Zagorac A , Pospihalj B , Munda M , Dzeroski S, et al .TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.BMC UROL. 2016 Jul 4;16(1):35. doi: 10.1186\/s12894-016-0160-8.","DOI":"10.1186\/s12894-016-0160-8"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_020","doi-asserted-by":"crossref","unstructured":"Y\u0131lmaz O, Berber U, Ok\u00e7elik S, Soydan H, Ate\u015f F and Karademir K. Turk TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens. J Urol. 2016 Jun; 42(2): 60\u201363. doi: 10.5152\/tud.2016.94763","DOI":"10.5152\/tud.2016.94763"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_021","doi-asserted-by":"crossref","unstructured":"Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802\u20131807.","DOI":"10.1093\/annonc\/mdt138"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_022","doi-asserted-by":"crossref","unstructured":"Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Pathol. 2007;20:467\u2013473.","DOI":"10.1038\/modpathol.3800759"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_023","doi-asserted-by":"crossref","unstructured":"Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, et al. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006;8:826\u2013832.","DOI":"10.1593\/neo.06427"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_024","doi-asserted-by":"crossref","unstructured":"Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26:2667\u20132673.","DOI":"10.1038\/sj.onc.1210070"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_025","doi-asserted-by":"crossref","unstructured":"Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006;66:10658\u201310663.","DOI":"10.1158\/0008-5472.CAN-06-1871"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_026","doi-asserted-by":"crossref","unstructured":"Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim R,I et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 2006;66:10242\u201310246.","DOI":"10.1158\/0008-5472.CAN-06-1986"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_027","doi-asserted-by":"crossref","unstructured":"Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97: 1690\u20135.","DOI":"10.1038\/sj.bjc.6604054"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_028","doi-asserted-by":"crossref","unstructured":"FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008;8:230.","DOI":"10.1186\/1471-2407-8-230"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_029","doi-asserted-by":"crossref","unstructured":"Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69: 1400\u20136.","DOI":"10.1158\/0008-5472.CAN-08-2467"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_030","doi-asserted-by":"crossref","unstructured":"Park JY, Zheng W, Kim D, Jin Q.Cheng, bNagiKumar,a NazeelAhmadb, et al. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev 2007;31:359\u201365.","DOI":"10.1016\/j.cdp.2007.09.002"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_031","doi-asserted-by":"crossref","unstructured":"Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007;26:6560\u20135.","DOI":"10.1038\/sj.onc.1210472"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_032","doi-asserted-by":"crossref","unstructured":"Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, et al. DNA hypomethylation arises later in prostate cancer DNA Methylation and ERG Expression in Prostate Cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008;68:8954\u201367.","DOI":"10.1158\/0008-5472.CAN-07-6088"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_033","unstructured":"Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Z\u00f6chbauer-M\u00fcller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514\u20139."},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_034","doi-asserted-by":"crossref","unstructured":"Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, et al. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 2011;129:2454\u201362.","DOI":"10.1002\/ijc.25908"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_035","doi-asserted-by":"crossref","unstructured":"Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma, J Urol. 2003 Mar;169(3):1138\u201342","DOI":"10.1097\/01.ju.0000049627.90307.4d"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_036","doi-asserted-by":"crossref","unstructured":"Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 2004 Sep;12(3):631\u20137.","DOI":"10.3892\/or.12.3.631"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_037","doi-asserted-by":"crossref","unstructured":"Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Volume 205, Issue 2, March 2004, Pages 181\u20138","DOI":"10.1016\/j.canlet.2003.11.027"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_038","doi-asserted-by":"crossref","unstructured":"Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J M, Benson MC,, Regina M, et al. DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer DNA Cell Biol. 2012 Feb; 31(2): 187\u2013192.","DOI":"10.1089\/dna.2011.1311"},{"key":"2026101418572579994_j_bjmg-2026-0014_ref_039","doi-asserted-by":"crossref","unstructured":"Zhou M1, Tokumaru Y, Sidransky D, Epstein JI. Quantitative GSTP1 methylation levels correlate with Gleason grade and tumor volume in prostate needle biopsies. J Urol. 2004 Jun;171(6 Pt 1):2195\u20138.","DOI":"10.1097\/01.ju.0000127728.71350.36"}],"container-title":["Balkan Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/bjmg-2026-0014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:57:38Z","timestamp":1792004258000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/bjmg-2026-0014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,10,14]]},"published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["10.2478\/bjmg-2026-0014"],"URL":"https:\/\/doi.org\/10.2478\/bjmg-2026-0014","relation":{},"ISSN":["2199-5761"],"issn-type":[{"value":"2199-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}